My other venture 9xchange had a a busy week. We announced a partnership with AI-enabled drug discovery company BenevolentAI at the Biomed conference here in Tel Aviv.
On 9xchange, we match buyers and sellers of pharmaceutical drugs that are still in development. Sometimes, a drug no longer fits the strategy of a pharma company, sometimes, a drug fails clinical trials for a specific disease, but might still work for another one.
BenevolentAI has technology to find potential new indications for drugs. Drugs posted on the platform are exposed to its AI engine and results are fed back into 9xchange to broaden the number of matches between buyers and sellers, now taken into account newly discovered indications for which this drug might work.